|
|
 |
|
Viewing report
|
|
|
|
A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market
Bioseeker, June 2010, Pages: 838
This report comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. The report extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer. Significantly new prostate cancer therapies will soon come to challenge old established drugs on the market. Four out of five target strategies in Phase III and nine out of ten in Phase II are novel and innovative in their design.
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in prostate cancer by:
- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area strategies
- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any prostate cancer drug to ensure that the optimal market conditions exist by the time the product is commercialized.
Customers who bought this item also bought
Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
Drug Delivery in Cancer - Technologies, Markets and Companies
Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline
Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others
Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
|
|
|
|
